Contact
Please use this form to send email to PR contact of this press release:
Anavex Life Sciences Announces Data on 41-Week Treatment of ANAVEX 2-73 for Patients with Alzheimer’s Disease − Investigational Treatment suggests to curb Cognitive and Functional Decline
TO: